Department of Internal Medicine, Fairview Hospital, 18101 Lorain Road, Cleveland, OH 44111, USA.
Med Oncol. 2012 Dec;29(5):3594-6. doi: 10.1007/s12032-012-0272-2. Epub 2012 Jun 9.
Sunitinib is an oral multiple tyrosine kinase receptor inhibitor. It is usually well tolerated but can cause fatigue, malaise, and rash. Sunitinib-induced cardiotoxicity has been well described, but nephrotoxicity is very rare. Here, we report a rare case of acute renal failure caused by sunitinib therapy in a 73-year-old Caucasian female who was enrolled in a phase II trial of sunitinib therapy for clear cell ovarian cancer. At presentation, her blood urea nitrogen (BUN) was 91 mg/dl and creatinine was 9.2 mg/dl. Sunitinib therapy was discontinued, and she was treated conservatively with intravenous fluid. Creatinine gradually returned to normal, and fatigue resolved. She was diagnosed with sunitinib-induced acute renal failure. The nephrologists and oncologists should be aware of sunitinib-induced rare nephrotoxicity, and patients should be closely monitored.
舒尼替尼是一种口服多靶点酪氨酸激酶抑制剂。通常耐受性良好，但可引起乏力、不适和皮疹。舒尼替尼引起的心脏毒性已有充分描述，但肾毒性非常罕见。在此，我们报告了一例 73 岁白人女性在接受舒尼替尼治疗透明细胞卵巢癌的 II 期临床试验时发生舒尼替尼治疗引起的急性肾衰竭的罕见病例。就诊时，她的血尿素氮（BUN）为 91mg/dl，肌酐为 9.2mg/dl。停用舒尼替尼治疗，并给予静脉补液保守治疗。肌酐逐渐恢复正常，乏力缓解。她被诊断为舒尼替尼引起的急性肾衰竭。肾病学家和肿瘤学家应该意识到舒尼替尼引起的罕见肾毒性，并密切监测患者。
